• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

瑞典轻链淀粉样变性的流行病学和临床结局:一项全国范围内基于人群的研究。

Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.

机构信息

Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Janssen Global Services, Titusville, New Jersey, USA.

出版信息

Eur J Haematol. 2023 Nov;111(5):697-705. doi: 10.1111/ejh.14063. Epub 2023 Aug 2.

DOI:10.1111/ejh.14063
PMID:37533343
Abstract

OBJECTIVES

This study evaluated data from six Swedish national registries to fill current evidence gaps on the epidemiology, clinical burden, and overall survival (OS) associated with light-chain (AL) amyloidosis.

METHODS

Patients newly diagnosed with AL amyloidosis were identified using six linked Swedish nationwide population-based registers. For each case, individuals from the general population were selected and matched with a maximum ratio of 1:5 based on age, sex, calendar year, and county.

RESULTS

846 patients newly diagnosed with AL amyloidosis and 4227 demographically matched individuals were identified. From 2011 to 2019, annual AL amyloidosis incidence increased from 10.5 to 15.1 cases per million. At baseline, patients with AL amyloidosis had a significantly higher disease burden including higher rates of cardiac and renal failure relative to the comparison group. Among patients with AL amyloidosis, 21.5% had incident heart failure and 17.1% had incident renal failure after initial diagnosis. Median OS for patients with AL amyloidosis was 56 months versus not reached in the matched general population comparison group.

CONCLUSION

The incidence of newly diagnosed AL amyloidosis in Sweden increased over time with AL amyloidosis being associated with a higher risk of cardiac/renal failure and all-cause mortality compared with the general population.

摘要

目的

本研究利用来自瑞典六个全国性登记处的数据,填补轻链(AL)淀粉样变性相关流行病学、临床负担和总体生存(OS)的现有证据空白。

方法

使用六个瑞典全国性基于人群的登记处来确定新诊断为 AL 淀粉样变性的患者。对于每例病例,从普通人群中选择个体,并根据年龄、性别、日历年份和县与最大 1:5 的比例相匹配。

结果

确定了 846 例新诊断的 AL 淀粉样变性患者和 4227 名年龄、性别、年份和地区匹配的个体。2011 年至 2019 年,每年的 AL 淀粉样变性发病率从每百万 10.5 例增加到 15.1 例。在基线时,与对照组相比,AL 淀粉样变性患者的疾病负担明显更高,包括心力衰竭和肾功能衰竭的发生率更高。在 AL 淀粉样变性患者中,21.5%的患者在初始诊断后出现心力衰竭,17.1%的患者出现肾功能衰竭。AL 淀粉样变性患者的中位 OS 为 56 个月,而匹配的普通人群对照组未达到。

结论

瑞典新诊断的 AL 淀粉样变性的发病率随时间增加,与普通人群相比,AL 淀粉样变性患者发生心力衰竭/肾功能衰竭和全因死亡率的风险更高。

相似文献

1
Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.瑞典轻链淀粉样变性的流行病学和临床结局:一项全国范围内基于人群的研究。
Eur J Haematol. 2023 Nov;111(5):697-705. doi: 10.1111/ejh.14063. Epub 2023 Aug 2.
2
A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan.一项基于人群的队列研究,探讨了台湾地区轻链淀粉样变的流行病学。
Sci Rep. 2022 Sep 21;12(1):15736. doi: 10.1038/s41598-022-18990-3.
3
Clinical and laboratory profile of renal amyloidosis: A single-center experience.肾淀粉样变性的临床和实验室特征:单中心经验
Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1065-1072. doi: 10.4103/1319-2442.243966.
4
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.真实世界中淀粉样变心肌病患者的治疗模式、费用和结局:Optum EHR 和商业索赔数据库分析。
Amyloid. 2023 Jun;30(2):161-168. doi: 10.1080/13506129.2022.2137400. Epub 2022 Oct 25.
5
[A clinical retrospective analysis of newly diagnosed multiple myeloma patients with systemic light chain amyloidosis].新诊断的多发性骨髓瘤合并系统性轻链淀粉样变性患者的临床回顾性分析
Zhonghua Xue Ye Xue Za Zhi. 2022 Apr 14;43(4):330-335. doi: 10.3760/cma.j.issn.0253-2727.2022.04.011.
6
Incidence and survival in non-hereditary amyloidosis in Sweden.瑞典非遗传性淀粉样变性的发病率和存活率。
BMC Public Health. 2012 Nov 13;12:974. doi: 10.1186/1471-2458-12-974.
7
Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.轻链淀粉样变性的治疗模式和结局:阿根廷淀粉样变性报告中的机构登记。
PLoS One. 2022 Oct 27;17(10):e0274578. doi: 10.1371/journal.pone.0274578. eCollection 2022.
8
State-of-the-art review on AL amyloidosis in Western Countries: Epidemiology, health economics, risk assessment and therapeutic management of a rare disease.西方国家 AL 淀粉样变的最新研究进展:一种罕见病的流行病学、卫生经济学、风险评估和治疗管理。
Blood Rev. 2023 May;59:101040. doi: 10.1016/j.blre.2023.101040. Epub 2023 Jan 20.
9
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.心脏淀粉样变:被忽视、被低估且可治疗。
Annu Rev Med. 2020 Jan 27;71:203-219. doi: 10.1146/annurev-med-052918-020140.
10
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015.明尼苏达州奥姆斯特德县 1990 年至 2015 年 AL 淀粉样变性的发病率。
Mayo Clin Proc. 2019 Mar;94(3):465-471. doi: 10.1016/j.mayocp.2018.08.041. Epub 2019 Jan 31.

引用本文的文献

1
Incidence and prevalence of light chain amyloidosis in the United States in 2019-2021 using Optum EHR data.利用Optum电子健康记录数据统计2019 - 2021年美国轻链淀粉样变性的发病率和患病率。
Sci Rep. 2025 Jul 11;15(1):25149. doi: 10.1038/s41598-025-09498-7.
2
Characterizing Heart Failure Across the Spectrum of the Preserved Ejection Fraction: Does Heart Failure With Supranormal Ejection Fraction Exist? Data From the Swedish Heart Failure Registry.射血分数保留范围内心力衰竭的特征描述:射血分数超常的心力衰竭是否存在?来自瑞典心力衰竭登记处的数据。
J Am Heart Assoc. 2025 Mar 18;14(6):e037502. doi: 10.1161/JAHA.124.037502. Epub 2025 Mar 13.
3
Epidemiological perspectives of amyloidosis in Argentina: a cohort study analysing incidence and mortality patterns among a population affiliated to a medical care programme.
阿根廷淀粉样变性病的流行病学视角:一项队列研究,分析参加医疗保健计划人群的发病率和死亡率模式。
BMJ Public Health. 2025 Jan 27;3(1):e001047. doi: 10.1136/bmjph-2024-001047. eCollection 2025 Jan.
4
A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis.一种简单的衰弱评分可预测系统性AL淀粉样变性的生存率和早期死亡率。
Cancers (Basel). 2024 Apr 26;16(9):1689. doi: 10.3390/cancers16091689.